FDA Classifies Fancy Blood Cancer Gene Test
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting a special kind of test that spots chromosome problems in blood cancer patients into a safer, more controlled category called Class II. This change helps make sure the test works well and is safe, while also making it easier for new and helpful devices to reach patients faster. Labs and device makers should get ready for these new rules, which aim to speed up access without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FISH Chromosome Test Moved to Class II
The FDA is officially classifying the fluorescence in situ hybridization (FISH) test that detects chromosomal abnormalities in patients with hematologic malignancies as Class II (special controls). The Agency says this classification provides reasonable assurance of the test's safety and effectiveness and is intended to enhance patient access to these devices while reducing regulatory burdens and speeding access without extra costs.
Labs and Makers Face Lower Regulatory Burden
The FDA says reclassifying this FISH-based chromosomal abnormality test into Class II (special controls) reduces regulatory burdens for labs and device makers and should make it easier for new devices to reach patients faster. The rule tells labs and device makers to prepare for the new classification and frames the change as speeding access without extra costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Attenuation
The FDA is officially putting the cream used to block x-rays into a special safety category called Class II. This means the cream will have clear rules to keep it safe and effective, making it easier for patients to get new and helpful products. This change helps companies by cutting some red tape without costing extra time or money.
Next: 2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections
The FDA is officially putting the herpes simplex virus test for brain infections into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get better access to this important tool. The change aims to make things smoother for companies without costing extra time or money.